ALK and non-small cell lung carcinoma: To this end, preclinical data show that in mouse models of ALK-rearranged NSCLC, treatment with an ALK vaccine, either alone or in combination with ALK TKIs or PD-1 pathway inhibitors, appears to be a safe and effective approach for prolonging overall survival [16].